Abcellera Biologics Inc (ABCL)vsRevolution Medicines Inc (RVMD)
ABCL
Abcellera Biologics Inc
$5.24
+8.71%
HEALTHCARE · Cap: $1.54B
RVMD
Revolution Medicines Inc
$141.81
-0.49%
HEALTHCARE · Cap: $30.30B
Smart Verdict
WallStSmart Research — data-driven comparison
Abcellera Biologics Inc generates 10025% more annual revenue ($75.13M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -194.9%. ABCL earns a higher WallStSmart Score of 41/100 (D).
ABCL
Hold41
out of 100
Grade: D
RVMD
Avoid24
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.8%
Fair Value
$8.88
Current Price
$5.24
$3.64 discount
Intrinsic value data unavailable for RVMD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 788.0% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Earnings expanding 45.9% YoY
Safe zone — low bankruptcy risk
Areas to Watch
Smaller company, higher risk/reward
ROE of -14.5% — below average capital efficiency
Negative free cash flow — burning cash
Currently unprofitable
Trading at 17.1x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABCL
The strongest argument for ABCL centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 788.0% demonstrates continued momentum.
Bull Case : RVMD
The strongest argument for RVMD centers on Altman Z-Score.
Bear Case : ABCL
The primary concerns for ABCL are Market Cap, Return on Equity, Free Cash Flow.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
ABCL profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.
RVMD carries more volatility with a beta of 1.41 — expect wider price swings.
ABCL is growing revenue faster at 788.0% — sustainability is the question.
ABCL generates stronger free cash flow (-45M), providing more financial flexibility.
Bottom Line
ABCL scores higher overall (41/100 vs 24/100) and 788.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abcellera Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AbCellera Biologics Inc. develops an antibody discovery platform. The company is headquartered in Vancouver, Canada.
Visit Website →Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?